No Data
No Data
Express News | Unicycive Therapeutics Shares Are Trading Higher After the United States Patent and Trademark Office Granted the Company a Patent on UNI-494 to Treat Acute Kidney Injury
Unicycive Secures Patent for Kidney Disease Treatment UNI-494, Valid Until 2040
Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or "Unicycive"), today announced the issuance
Express News | Unicycive Therapeutics Inc - Patent, Valid Until 2040
Express News | Unicycive Therapeutics Granted Patent on Uni-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (Uspto)
Maxim Group Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Maintains Target Price $4
Maxim Group analyst Jason McCarthy maintains $Unicycive Therapeutics(UNCY.US)$ with a buy rating, and maintains the target price at $4.According to TipRanks data, the analyst has a success rate of 24.
Buy Rating Affirmed for Unicycive Therapeutics Amid Positive Clinical Feedback and Strong Market Entry Potential
No Data